|
Turkish Society of Cardiology
Young Cardiologists
President
Dr. Muzaffer Değertekin
Coordinator for the
Board of Directors
Dr. Ertuğrul Okuyan
Coordinator for the
Board of Directors
Dr. Can Yücel Karabay
Members
Dr. Adem Aktan
Dr. Gülşah Aktüre
Dr. Bayram Arslan
Dr. İnanç Artaç
Dr. Ahmet Oğuz Aslan
Dr. Görkem Ayhan
Dr. Ahmet Anıl Başkurt
Dr. Özkan Bekler
Dr. Oğuzhan Birdal
Dr. Yusuf Bozkurt Şahin
Dr. Serkan Bulgurluoğlu
Dr. Ümit Bulut
Dr. Veysi Can
Dr. Mustafa Candemir
Dr. Murat Çap
Dr. Göksel Çinier
Dr. Ali Çoner
Dr. Yusuf Demir
Dr. Ömer Furkan Demir
Dr. Murat Demirci
Dr. Ayşe İrem Demirtola Mammadli
Dr. Süleyman Çağan Efe
Dr. Mehmet Akif Erdöl
Dr. Kubilay Erselcan
Dr. Kerim Esenboğa
Dr. Duygu Genç
Dr. Kemal Göçer
Dr. Elif Güçlü
Dr. Arda Güler
Dr. Duygu İnan
Dr. Hasan Burak İşleyen
Dr. Muzaffer Kahyaoğlu
Dr. Sedat Kalkan
Dr. Yücel Kanal
Dr. Özkan Karaca
Dr. Ahmet Karaduman
Dr. Mustafa Karanfil
Dr. Ayhan Kol
Dr. Fatma Köksal
Dr. Mevlüt Serdar Kuyumcu
Dr. Yunus Emre Özbebek
Dr. Ahmet Özderya
Dr. Yasin Özen
Dr. Ayşenur Özkaya İbiş
Dr. Çağlar Özmen
Dr. Selvi Öztaş
Dr. Hasan Sarı
Dr. Serkan Sivri
Dr. Ali Uğur Soysal
Dr. Hüseyin Tezcan
Dr. Nazlı Turan
Dr. Berat Uğuz
Dr. Örsan Deniz Urgun
Dr. İdris Yakut
Dr. Mustafa Yenerçağ
Dr. Mehmet Fatih Yılmaz
Dr. Yakup Yiğit
Dr. Mehmet Murat Yiğitbaşı
Bulletin Editors
Dr. Muzaffer Değertekin
Dr. Bülent Mutlu
Dr. Süleyman Çağan Efe
Dr. Duygu İnan
Dr. Alper Karakuş
Dr. Sedat Kalkan
Dr. Göksel Çinier
Contributors
Dr. Selin Çakır
Dr. Ezgi Güzel
Dr. Numan Kılıç
Dr. Cansu Öztürk
Dr. Bilal Ülker
Dr. Gözde Yılmaz
|
| |
|
|
|
Three-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic StenosisTürk Kardiyoloji Derneği Genç Kardiyologlar Bülteni - Three-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis (Dr. Bilal Ülker)Three-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis
Dr. Bilal Sönmez
Published in Congress: ACC 2023
Link: https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017
Objective:
Randomized data comparing the outcomes of transcatheter aortic valve replacement (TAVR) with surgery after 2 years in patients at low surgical risk are limited, and this study aimed to evaluate the 3-year clinical and echocardiographic outcomes of the “Evolut Low Risk” trial.
Methods:
Patients were randomized to TAVR and surgical intervention groups and the primary endpoint was all-cause mortality or stroke with sequelae.
Results:
The study enrolled 1414 patients (730 TAVR; 684 surgery). The mean age of patients was 74 years and 35% were women. The primary endpoint occurred in 7.4% of TAVR patients and 10.4% of surgical patients (HR, 0.70; 95% CI, 0.49-1.00; p=0.051). The frequency of mild paravalvular regurgitation (20.3% TAVR, 2.5% surgery) and pacemaker implantation (23.2% TAVR, 9.1% surgery; p<0.001) was lower in the surgical group. Moderate or greater paravalvular regurgitation was less than 1% in both groups and did not differ significantly. Valve function improved significantly at 3 years in patients who underwent TAVR (mean gradient 9.1 mmHg TAVR, 12.1 mmHg surgery; p<0.001).
Discussion:
Overall, in the “Evolut Low Risk” trial, TAVR was more successful than surgery in terms of all-cause mortality or stroke with sequelae at 3 years.
|
